AAV2-GDNF Gene Therapy for Parkinson's Disease

Human Gene TherapyVol. 20, No. 5 EditorialAAV2-GDNF Gene Therapy for Parkinson's DiseaseSharona Even Ram and Eithan GalunSharona Even RamHuman Embryonic Stem Cell Center, Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Hospital, Jerusalem, 91120, Israel.Search for more papers by this author and Eithan GalunGoldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Hospital, Jerusalem, 91120, Israel.Search for more papers by this authorPublished Online:23 Oct 2009https://doi.org/10.1089/hum.2009.1599AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View article"AAV2-GDNF Gene Therapy for Parkinson's Disease." , 20(5), pp. 430–431FiguresReferencesRelatedDetailsCited byTreatment of experimental autoimmune encephalomyelitis using AAV gene therapy by blocking T cell costimulatory pathwaysMolecular Therapy - Methods & Clinical Development, Vol. 25Functional Neuroprotection and Efficient Regulation of GDNF Using Destabilizing Domains in a Rodent Model of Parkinson’s DiseaseMolecular Therapy, Vol. 21, No. 12CLINICAL DEVELOPMENT OF AAV VECTORSGene Therapy and Regulation, Vol. 05, No. 01Pro-Survival Role for Parkinson's Associated Gene DJ-1 Revealed in Trophically Impaired Dopaminergic Neurons6 April 2010 | PLoS Biology, Vol. 8, No. 4 Volume 20Issue 5May 2009 InformationCopyright 2009, Mary Ann Liebert, Inc.To cite this article:Sharona Even Ram and Eithan Galun.AAV2-GDNF Gene Therapy for Parkinson's Disease.Human Gene Therapy.May 2009.430-431.http://doi.org/10.1089/hum.2009.1599Published in Volume: 20 Issue 5: October 23, 2009PDF download